Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ruriko Koto, Akihiro Nakajima, Hideki Horiuchi & Hisashi Yamanaka. (2021) Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data. Modern Rheumatology 31:1, pages 261-269.
Read now
Read now
Liza W Claus & Joseph J Saseen. (2018) Patient considerations in the management of gout and role of combination treatment with lesinurad. Patient Related Outcome Measures 9, pages 231-238.
Read now
Read now
Richard Sheer, Kyle D Null, Keith A Szymanski, Lavanya Sudharshan, Jennifer Banovic & Margaret K Pasquale. (2017) Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. ClinicoEconomics and Outcomes Research 9, pages 629-639.
Read now
Read now
K-H Yu, J-H Lai, P-N Hsu, D-Y Chen, C-J Chen & H-Y Lin. (2016) Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. Scandinavian Journal of Rheumatology 45:4, pages 304-311.
Read now
Read now
Articles from other publishers (15)
Nevin Hammam, Jing Li, Julia Kay, Zara Izadi, Jinoos Yazdany & Gabriela Schmajuk. (2023)
Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving
Long‐Term Urate‐Lowering
Therapy in the American College of Rheumatology
RISE
Registry
. Arthritis Care & Research 75:7, pages 1544-1552.
Crossref
Crossref
S. Scott Sutton, Joseph Magagnoli, Tammy H. Cummings & James W. Hardin. (2023) Odds of Achieving Target Serum Uric Acid Levels Among Gout Patients: The Role of Rurality in Outcomes and Treatment Adherence. Journal of Primary Care & Community Health 14, pages 215013192311673.
Crossref
Crossref
Ruriko Koto, Akihiro Nakajima, Hideki Horiuchi & Hisashi Yamanaka. (2020) Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data. Pharmacoepidemiology and Drug Safety 30:2, pages 157-168.
Crossref
Crossref
Hamish Farquhar, Ana B Vargas-Santos, Huai Leng Pisaniello, Mark Fisher, Catherine Hill, Angelo L Gaffo & Lisa K Stamp. (2021) Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review. Rheumatology Advances in Practice 5:1.
Crossref
Crossref
Ratchaya Lertnawapan & Kanon Jatuworapruk. (2020) Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout. Clinical Rheumatology 40:1, pages 255-262.
Crossref
Crossref
Zepeng Mu, Wei Wang, Jing Wang, Wenshan Lv, Ying Chen, Fang Wang, Xiaolong Yu, Yangang Wang, Bingfei Cheng & Zhongchao Wang. (2019) Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial. Clinical Rheumatology 38:12, pages 3511-3519.
Crossref
Crossref
Samantha S. R. Crossfield, Lana Yin Hui Lai, Sarah R. Kingsbury, Paul Baxter, Owen Johnson, Philip G. Conaghan & Mar Pujades-Rodriguez. (2019) Variation in methods, results and reporting in electronic health record-based studies evaluating routine care in gout: A systematic review. PLOS ONE 14:10, pages e0224272.
Crossref
Crossref
Garry G. Graham, Sophie L. Stocker, Diluk R.W. Kannangara & Richard O. Day. (2018) Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout. Current Rheumatology Reports 20:8.
Crossref
Crossref
Caroline L. Benn, Pinky Dua, Rachel Gurrell, Peter Loudon, Andrew Pike, R. Ian Storer & Ciara Vangjeli. (2018) Physiology of Hyperuricemia and Urate-Lowering Treatments. Frontiers in Medicine 5.
Crossref
Crossref
Fasih A. Hameed. 2018. Integrative Medicine. Integrative Medicine
689
696.e2
.
Jasvinder A. Singh, Rekha Ramachandaran, Shaohua Yu & Jeffrey R. Curtis. (2017) Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. BMC Cardiovascular Disorders 17:1.
Crossref
Crossref
Jun-ichi Oyama, Atsushi Tanaka, Yasunori Sato, Hirofumi Tomiyama, Masataka Sata, Tomoko Ishizu, Isao Taguchi, Takanori Kuroyanagi, Hiroki Teragawa, Nobukazu Ishizaka, Yumiko Kanzaki, Mitsuru Ohishi, Kazuo Eguchi, Yukihito Higashi, Hirotsugu Yamada, Koji Maemura, Junya Ako, Yasuko K. Bando, Shinichiro Ueda, Teruo Inoue, Toyoaki Murohara & Koichi Node. (2016) Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study. Cardiovascular Diabetology 15:1.
Crossref
Crossref
Hiroyuki Ito, Shinichi Antoku, Mariko Abe, Takashi Omoto, Masahiro Shinozaki, Shinya Nishio, Mizuo Mifune, Michiko Togane, Masaya Nakata & Tatsuya Yamashita. (2016) Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study. Internal Medicine 55:22, pages 3247-3256.
Crossref
Crossref
Eric Wise & Puja P. Khanna. (2015) The impact of gout guidelines. Current Opinion in Rheumatology 27:3, pages 225-230.
Crossref
Crossref
James E. Frampton. (2015) Febuxostat: A Review of Its Use in the Treatment of Hyperuricaemia in Patients with Gout. Drugs 75:4, pages 427-438.
Crossref
Crossref